Efficacy and ctDNA analysis in an updated cohort of patients with TRK fusion lung cancer treated with larotrectinib

被引：0

作者：

Hoejgaard, M. ^{[1
]}

Drilon, A. ^{[2
,3
]}

Lin, J. J. ^{[4
]}

Kummar, S. ^{[5
]}

Tan, D. S. W. ^{[6
]}

Patel, J. ^{[7
]}

Leyvraz, S. ^{[8
]}

Garcia, V. Moreno ^{[9
]}

Rosen, L. S. ^{[10
]}

Solomon, B. ^{[11
]}

Yachnin, J. ^{[12
]}

Liu, Y. ^{[13
,14
]}

Dai, M-S. ^{[15
]}

Norenberg, R. ^{[16
]}

Burcoveanu, D-I. ^{[17
]}

Yun, L. ^{[18
]}

Beckmann, G. ^{[19
]}

Mussi, C. E. ^{[20
]}

Shen, L. ^{[21
]}

机构：

[1] Rigshosp, Dept Oncol, Phase Unit 1, Copenhagen, Denmark

[2] Mem Sloan Kettering Canc Ctr, New York, NY USA

[3] Weill Cornell Med Coll, New York, NY USA

[4] MGH Massachusetts Gen Hosp, Thorac Oncol Dept, Boston, MA USA

[5] OHSU Knight Canc Inst, Div Hematol & Med Oncol, Ctr Hlth & Healing, Bldg 1 South Waterfront, Portland, OR USA

[6] NCCS Natl Canc Ctr Singapore, Med Oncol Dept, Singapore, Singapore

[7] Northwestern Univ, Dept Med, Chicago, IL USA

[8] Charite Univ Med Berlin, Dept Hematol Oncol & Tumor Immunol, Berlin, Germany

[9] Hosp Univ Fdn Jimenez Diaz, START Madrid FJD Early Phase Clin Trials Unit, Madrid, Spain

[10] UCLA, Hematol Oncol Santa Monica, Santa Monica, CA USA

[11] Avera Canc Inst, Div Hematol & Oncol, Sioux Falls, SD USA

[12] Karolinska Univ Hosp, Dept Oncol, Solna, Sweden

[13] Sichuan Univ, West China Hosp, Ctr Canc, Dept Thorac Oncol, Chengdu, Peoples R China

[14] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Chengdu, Peoples R China

[15] Tri Serv Gen Hosp, Divis Oncol, Taipei, Taiwan

[16] Chrestos Concept GmbH & Co KG, Stat, Essen, Germany

[17] Bayer Healthcare Pharmaceut Inc, Med Affairs Oncol, Basel, Switzerland

[18] Bayer HealthCare Pharmaceut Inc, Mississauga, ON, Canada

[19] Bayer AG Pharmaceut, Res & Dev Pharmaceut, Berlin, Germany

[20] Bayer SpA, Div Pharmaceut, Milan, Italy

[21] Peking Univ Canc Hosp & Inst, Dept Gastrointestinal Oncol, Beijing, Peoples R China

来源：

JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

15MO

引用

页码：S48 / S49

页数：2

共 50 条

[1] Updated efficacy and ctDNA analysis of patients with TRK fusion lung cancer treated with larotrectinib
Moreno, V.
Lin, J. J.
Tan, D. S. W.
Lassen, U. N.
Leyvraz, S.
Liu, Y.
Patel, J.
Rosen, L.
Solomon, B.
Rudolph, M.
Norenberg, R.
Schulz, A.
Fellous, M.
Brega, N.
Shen, L.
Kummar, S.
Drilon, A.
ANNALS OF ONCOLOGY, 2022, 33 : S60 - S60
[2] Updated Efficacy, Safety, and Biomarker Analysis in Patients with TRK Fusion Lung Cancer Treated with Larotrectinib
Lin, J. J.
Tan, D. S. W.
Kummar, S.
Moreno, V.
Leyvraz, S.
Dubashi, B.
Parambath, H.
Burcoveanu, D. -I.
Neu, N.
Leserer, S.
Seidel, H.
Mussi, C. E.
Shen, L.
Drilon, A.
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S77 - S77
[3] Updated efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion lung cancer.
Drilon, Alexander E.
Lin, Jessica Jiyeong
Kummar, Shivaani
Tan, Daniel Shao-Weng
Patel, Jyoti D.
Lassen, Ulrik Niels
Leyvraz, Serge
Moreno, Victor
Rosen, Lee S.
Solomon, Benjamin Maurice
Yachnin, Jeffrey
Liu, Yongmei
Dai, Ming-Shen
Norenberg, Ricarda
Fellous, Marc Mardoche
Mussi, Chiara Erminia
Shen, Lin
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[4] Long-term efficacy and genomic characteristics of patients with TRK fusion lung cancer treated with larotrectinib
Moreno Garcia, V.
Lin, J.
Patel, J.
Lassen, U.
Solomon, B.
Rosen, L.
Leyvraz, S.
Tan, D. S. W.
Reeves, J. A.
Beckmann, G.
Rudolph, M.
Wierzbinska, J.
Dima, L.
Brega, N.
Kummar, S.
Drilon, A.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S786 - S787
[5] Incidence of fractures in TRK fusion cancer patients treated with larotrectinib
Laetsch, T. W.
van Tilburg, C. M.
Kummar, S.
Dowlati, A.
Guiver, K.
Fellous, M.
Brega, N.
De La Cuesta, E.
Shurshalina, A.
Drilon, A.
Hong, D.
ANNALS OF ONCOLOGY, 2021, 32 : S601 - S601
[6] Updated efficacy and safety of larotrectinib in patients with TRK fusion salivary gland tumours
Hong, D. S.
Tahara, M.
Baik, C.
Bauman, J. R.
Gilbert, J.
Brose, M. S.
Grilley-Olson, J. E.
Patil, T.
McDermott, R.
Raez, L. E.
Johnson, J. M.
Shen, L.
Norenberg, R.
Dima, L.
Mussi, C.
Le, X.
Drilon, A. E.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S847 - S848
[7] Updated efficacy and safety of larotrectinib in patients with TRK fusion salivary gland tumours
Shen, L.
Hong, D. S.
Tahara, M.
Baik, C. S.
Bauman, J. R.
Gilbert, J.
Brose, M. S.
Grilley-Olson, J. E.
Patil, T.
McDermott, R. S.
Raez, L. E.
Johnson, J. M.
Norenberg, R.
Dima, L.
Mussi, C. E.
Le, X.
Drilon, A.
ANNALS OF ONCOLOGY, 2022, 33 : S1521 - S1522
[8] Efficacy and safety of larotrectinib in patients with TRK fusion breast cancer
Rosen, Ezra Y.
Italiano, Antoine
Juric, Dejan
Reeves, John A.
Dima, Laura
Brega, Nicoletta
Drilon, Alexander
CANCER RESEARCH, 2021, 81 (04)
[9] Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer
Qi, Changsong
Shen, Lin
Andre, Thierry
Chung, Hyun Cheol
Cannon, Timothy L.
Garralda, Elena
Italiano, Antoine
Rieke, Damian T.
Liu, Tianshu
Burcoveanu, Domnita-Ileana
Neu, Natascha
Mussi, Chiara E.
Xu, Rui-Hua
Hong, David S.
Drilon, Alexander
Berlin, Jordan
EUROPEAN JOURNAL OF CANCER, 2025, 220
[10] Efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion lung cancer
Drilon, A.
Moreno, V.
Patel, J.
Lassen, U. N.
Solomon, B.
Rosen, L.
Leyvraz, S.
Tan, D. S. W.
Reeves, J. A.
Dima, L.
Brega, N.
Kummar, S.
Farago, A. F.
ANNALS OF ONCOLOGY, 2020, 31 : S834 - S834

← 1 2 3 4 5 →